Back to search
Hereditary Spastic Paraplegia Type 50
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Hereditary Spastic Paraplegia Type 50 trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Hereditary Spastic Paraplegia Type 50 trials you may qualify forPhase 3, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of MELPIDA in individuals with Hereditary Spastic Para…
MELPIDA is proposed for the treatment of subjects with SPG50 and targets neuronal cells to deliver a fully functional human AP4M1 cDNA copy via intrathecal inje…